Company intelligence / Profile preview

EpiWatch

Ownership: Private
Development stage: Preclinical

Overview

EpiWatch has received FDA 510(k) clearance for its Apple Watch-based seizure detection app, which provides real-time monitoring and alerts for tonic-clonic seizures. The device also offers medication reminders, seizure logging, and mental health screening features. It aims to reduce the risk of injury or death from seizures by enabling rapid intervention[1][4]. The company’s solution has been clinically tested and validated in partnership with Johns Hopkins University[4]. Early user feedback highlights increased independence for patients and peace of mind for caregivers[1]. There are no publicly disclosed clinical trial results beyond regulatory clearance.

Therapeutic areas: Neurology
Modalities: DeviceDigital health platform
Industry: Physiological Monitoring

Partnerships

Johns Hopkins University (spin-out/clinical validation)[4]

Beyond the preview

Go deeper on EpiWatch.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiWatch.

Explore the full profile